In the clinic, therapeutic effects for BA analogs and synthetic FXR agonists on various liver injury and metabolic disorders, including primary biliary cholangitis, nonalcoholic fatty liver disease, nonalcohol hepatitis, and lipodystrophy, have been reported [51]. This evidence concerns the gene NR1H4 and primary biliary cholangitis.